

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

Volume 39, Number 1, January 2019

Contents

Reviews

- Evolution of Cancer Progression in the Context of Darwinism. L. LACINA, M. ČOMA, B. DVOŘÁNKOVÁ, O. KODET, N. MELEGOVÁ, P. GÁL, K. SMETANA JR (*Prague; Vestec, Czech Republic; Košice; Bratislava, Slovak Republic*) 1
- An Update on the Current Role of High Resolution Anoscopy in Patients With Anal Dysplasia. A. GUDUR, D. SHANMUGANANDAMURTHY, Z. SZEP, J.L. POGGIO (*Philadelphia, PA, USA*) 17
- Anticoagulant Therapy for Disseminated Intravascular Coagulation After Gastrointestinal Surgery. D. HASHIMOTO, T. OKAWA, R. MARUYAMA, F. MATSUMURA, Y. SHIBATA, H. KOHROGI (*Kumamoto; Omuta, Japan*) 25
- MicroRNA Expression in the Progression and Aggressiveness of Papillary Thyroid Carcinoma. A. ZEMBSKA, A. JAWIARCZYK-PRZYBYŁOWSKA, B. WOJTCZAK, M. BOLANOWSKI (*Wroclaw, Poland*) 33
- Bioactive Sphingolipids as Biomarkers Predictive of Disease Severity and Treatment Response in Cancer: Current Status and Translational Challenges. M. SEDIĆ, P. GRBČIĆ, S. KRALJEVIĆ PAVELIĆ (*Rijeka, Croatia*) 41

Experimental Studies

- Combination of Biochanin A and Temozolomide Impairs Tumor Growth by Modulating Cell Metabolism in Glioblastoma Multiforme. V. DESAI, A. JAIN, H. SHAGHAGHI, R. SUMMER, J.C.K. LAI, A. BHUSHAN (*Philadelphia, PA; Pocatello, ID, USA*) 57
- A Single Nucleotide Polymorphism in *SLC7A5* Was Associated With Clinical Response in Multiple Myeloma Patients. M.J. POI, J. LI, J.A. JOHNSON, Y.K. CHO, D.W. SBOROV, M.A. PHELPS, C.C. HOFMEISTER (*Columbus, OH; Salt Lake City, UT; Atlanta, GA, USA*) 67

Contents continued on the back cover

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment



ISSN (print): 0250-7005
ISSN (online): 1791-7530

Editorial Board

- P. A. ABRAHAMSSON, Malmö, Sweden
B. B. AGGARWAL, Houston, TX, USA
T. AKIMOTO, Kashiwa, Chiba, Japan
P. Z. ANASTASIADIS, Jacksonville, FL, USA
A. ARGIRIS, San Antonio, TX, USA
J. P. ARMAND, Toulouse, France
V. I. AVRAMIS, Los Angeles, CA, USA
D.-T. BAU, Taichung, Taiwan, ROC
G. BAUER, Freiburg, Germany
E. E. BAULIEU, Le Kremlin-Bicetre, France
E. J. BENZ, Jr., Boston, MA, USA
J. BERGH, Stockholm, Sweden
F. T. BOSMAN, Lausanne, Switzerland
M. BOUVET, La Jolla, CA, USA
J. BOYD, Miami, FL, USA
G. BROICH, Monza, Italy
Ø. S. BRULAND, Oslo, Norway
J. M. BUATTI, Iowa City, IA, USA
M. M. BURGER, Basel, Switzerland
M. CARBONE, Honolulu, HI, USA
C. CARLBERG, Kuopio, Finland
J. CARLSSON, Uppsala, Sweden
A. F. CHAMBERS, London, ON, Canada
P. CHANDRA, Frankfurt am Main, Germany
L. CHENG, Indianapolis, IN, USA
J.-G. CHUNG, Taichung, Taiwan, ROC
R. CLARKE, Washington, DC, USA
E. DE CLERCQ, Leuven, Belgium
W. DEN OTTER, Amsterdam, The Netherlands
E. P. DIAMANDIS, Toronto, ON, Canada
G. TH. DIAMANDOPOULOS, Boston, MA, USA
L. EGEVAD, Stockholm, Sweden
D. W. FELSHER, Stanford, CA, USA
J. A. FERNANDEZ-POL, Chesterfield, MO, USA
I. J. FIDLER, Houston, TX, USA
A. P. FIELDS, Jacksonville, FL, USA
H. FU, Atlanta, GA, USA
B. FUCHS, Zurich, Switzerland
D. FUCHS, Innsbruck, Austria
D. FUKUMURA, Boston, MA, USA
G. GABBIANI, Geneva, Switzerland
R. GANAPATHI, Charlotte, NC, USA
A. F. GAZDAR, Dallas, TX, USA
A. GIORDANO, Philadelphia, PA, USA
G. GITSCH, Freiburg, Germany
M. GNANT, Vienna, Austria
R. H. GOLDFARB, Guilford, CT, USA
A. HELLAND, Oslo, Norway
L. HELSON, Quakertown, PA, USA
R. HENRIKSSON, Umeå, Sweden
R. M. HOFFMAN, San Diego, CA, USA
S. C. JHANWAR, New York, NY, USA
J. V. JOHANNESSON, Oslo, Norway
R. JONES, London, UK
B. KAINA, Mainz, Germany
P. -I. KELLOKUMPU-LEHTINEN, Tampere, Finland
D. G. KIEBACK, Schleswig, Germany
R. KLAPDOR, Hamburg, Germany
H. KOBAYASHI, Bethesda, MD, USA
S. D. KOTTARIDIS, Athens, Greece
G. R. F. KRUEGER, Köln, Germany
Pat M. KUMAR, Manchester, UK
Shant KUMAR, Manchester, UK
O. D. LAERUM, Bergen, Norway
F. J. LEJEUNE, Lausanne, Switzerland
S. LINDER, Linköping, Sweden
L. F. LIU, Piscataway, NJ, USA
D. M. LOPEZ, Miami, FL, USA
E. LUNDGREN, Umeå, Sweden
Y. MAEHARA, Fukuoka, Japan
J. MAHER, London, UK
J. MARESCAUX, Strasbourg, France
J. MARK, Skövde, Sweden
S. S. MARTIN, Baltimore, MD, USA
S. MITRA, Houston, TX, USA
S. MIYAMOTO, Fukuoka, Japan
S. MONCADA, Manchester, UK
M. MUELLER, Villingen-Schwenningen, Germany
F. M. MUGGIA, New York, NY, USA
M. NAMIKI, Kanazawa, Ishikawa, Japan
R. NARAYANAN, Boca Raton, FL, USA
K. NILSSON, Uppsala, Sweden
S. PATHAK, Houston, TX, USA
J. L. PERSSON, Malmö, Sweden
G. J. PILKINGTON, Portsmouth, UK
C. D. PLATSOUKAS, Norfolk, VA, USA
A. POLLIACK, Jerusalem, Israel
D. RADES, Lübeck, Germany
M. RIGAUD, Limoges, France
U. RINGBORG, Stockholm, Sweden
M. ROSELLI, Rome, Italy
S.T. ROSEN, Duarte, CA, USA
A. SCHAUER, Göttingen, Germany
M. SCHNEIDER, Wuppertal, Germany
J. SEHOULI, Berlin, Germany
A. SETH, Toronto, ON, Canada
G. V. SHERBET, Newcastle-upon-Tyne, UK
A. SLOMINSKI, Birmingham, AL, USA
G.-I. SOMA, Kagawa, Japan
G. S. STEIN, Burlington, VT, USA
T. STIGBRAND, Umeå, Sweden
T. M. THEOPHANIDES, Athens, Greece
P. M. UELAND, Bergen, Norway
H. VAN VLIERBERGHE, Ghent, Belgium
R. G. VILE, Rochester, MN, USA
M. WELLER, Zurich, Switzerland
J. WESTERMARCK, Turku, Finland
B. WESTERMARK, Uppsala, Sweden
Y. YEN, Taipei, Taiwan, ROC
M.R.I. YOUNG, Charleston, SC, USA
B. ZUMOFF, New York, NY, USA
G. J. DELINASIOS, Athens, Greece
Managing Editor and
Executive Publisher
J. G. DELINASIOS, Athens, Greece
Managing Editor (1981-2016)

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389.

U.S. Branch: Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA.

E-mails: Editorial Office: journals@iia-anticancer.org

Managing Editor: editor@iia-anticancer.org

ANTICANCER RESEARCH supports: (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR; Kapandriti, Attiki, Greece); and (b) the organization of the International Conferences of Anticancer Research. The IIAR is a member of UICC. For more information about ANTICANCER RESEARCH, IIAR and the Conferences, please visit the IIAR website: www.iia-anticancer.org

Publication Data: ANTICANCER RESEARCH (AR) is published bimonthly from January 1981 to December 2008 and monthly from January 2009. Each annual volume comprises 12 issues. Annual Author and Subject Indices are included in the last issue of each volume. ANTICANCER RESEARCH Vol. 24 (2004) and onwards appears online with Stanford University HighWire Press from April 2009.

Copyright: On publication of a manuscript in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal.

Annual Subscription Rates 2018 per volume: Institutional subscription US\$ 1,898.00 (online) or US\$ 2,277.00 (print & online). Personal subscription US\$ 897.00 (online) or US\$ 1,277.00 (print & online). Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-37, 1981-2017) are available at 50% discount on the above rates.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the Publisher. (e-mail: subscriptions@iia-anticancer.org)

Advertising: All correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Obtaining permission to reuse or reproduce our content: AR has partnered with Copyright Clearance Center (CCC) to make it easy to secure permissions to reuse its content. Please visit www.copyright.com and enter the title that you are requesting permission for in the 'Get Permission' search box. For assistance in placing a permission request, Copyright Clearance Center can be contacted directly at: Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. Phone: +1-978-750-8400. Fax: +1-978-646-8600. E-mail: info@copyright.com.

The Editors and Publishers of ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

Copyright© 2019, International Institute of Anticancer Research

(Dr. George J. Delinasios). All rights reserved.

D.T.P. BY IIAR

PRINTED BY ENTYP0, ATHENS, GREECE. PRINTED ON ACID-FREE PAPER

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment
ISSN (print): 0250-7005, ISSN (online): 1791-7530

VOLUME 39
2019

Editorial Board

P. A. Abrahamsson	Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden
B. B. Aggarwal	Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
T. Akimoto	Division of Particle Therapy and Department of Radiation Oncology, National Cancer Center East, Kashiwa, Chiba, Japan
P. Z. Anastasiadis	Department of Cancer Biology, Mayo Cancer Center, Jacksonville, FL, USA
A. Argiris	Division of Hematology/Oncology, UT Health Science Center at San Antonio, San Antonio, TX, USA
J. P. Armand	Institut Claudius Regaud, Toulouse, France
V. I. Avramis	Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA
D.-T. Bau	Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan, ROC
G. Bauer	Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany
E. E. Baulieu	INSERM U488 and College de France, Le Kremlin-Bicetre, France
E. J. Benz, Jr.	Dana-Farber Cancer Institute, Boston, MA, USA
J. Bergh	Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden
F. T. Bosman	Institute of Pathology, University of Lausanne, Switzerland
M. Bouvet	Department of Surgery, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA
J. Boyd	Department of Human and Molecular Genetics, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
G. Broich	Gruppo Policlinico di Monza, Monza, Italy
Ø. S. Bruland	Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway
J. M. Buatti	Department of Radiation Oncology, University of Iowa, Iowa City, IA, USA
M. M. Burger	Novartis, Basel, Switzerland
M. Carbone	Cancer Research Center of Hawaii, Honolulu, HI, USA
C. Carlberg	Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
J. Carlsson	Department of Biomedical Radiation Sciences, Uppsala University, Sweden
A. F. Chambers	Department of Oncology, London Regional Cancer Center, London, Ontario, Canada
P. Chandra	Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany
L. Cheng	Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA
J.-G. Chung	Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC
R. Clarke	Georgetown University Medical Center, Washington, DC, USA
E. De Clercq	Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
W. Den Otter	VUMC, Department of Urology, Amsterdam, The Netherlands
E. P. Diamandis	Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
G. Th. Diamandopoulos	Department of Pathology, Harvard Medical School, Boston, MA, USA
L. Egevad	Department of Pathology, Karolinska University Hospital, Stockholm, Sweden
D. W. Felsher	Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
J. A. Fernandez-Pol	Metalloproteomics, LLC, Chesterfield, MO, USA
I. J. Fidler	Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
A. P. Fields	Department of Cancer Biology, College of Medicine, Mayo Clinic, Jacksonville, FL, USA
H. Fu	Discovery and Developmental Therapeutics Program of Winship Cancer Institute, Emory University, Atlanta, GA, USA
B. Fuchs	Balgrist University Hospital, Zurich, Switzerland
D. Fuchs	Center for Chemistry and Biomedicine, Innsbruck Medical University, Innsbruck, Austria

D. Fukumura	Edwin L. Steele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA
G. Gabbiani	Department of Pathology, University of Geneva, Switzerland
R. Ganapathi	Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA
A. F. Gazdar	Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas, TX, USA
A. Giordano	Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA
G. Gitsch	Department of Gynecology and Obstetrics, University of Freiburg, Germany
M. Gnant	Department of Surgery, Medical University of Vienna, Austria
R. H. Goldfarb	R. H. Goldfarb Sopherion Therapeutics, LLC and Translational Oncology and ImmunoEngineering Consulting, Guilford, CT, USA
A. Helland	Oslo University Hospital-Radium Hospital, Oslo, Norway
L. Helson	Sign Path Pharma, Inc., Quakertown, PA, USA
R. Henriksson	Department of Experimental Oncology, Umeå University, Umeå, Sweden
R. M. Hoffman	Department of Surgery, University of California, San Diego, CA, USA
S. C. Jhanwar	Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J. V. Johannessen	Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
R. Jones	Sarcoma Unit, Royal Marsden Hospital, London, UK
B. Kaina	Institute of Toxicology, University of Mainz, Germany
P. -L. Kellokumpu-Lehtinen	Department of Oncology and Radiotherapy, Tampere University Hospital, Tampere, Finland
D. G. Kieback	Helios Medical Center Schleswig, Schleswig, Germany
R. Klapdor	Medical Clinic, University of Hamburg, Germany
H. Kobayashi	Laboratory of Molecular Theranostics, NCI/NIH, Bethesda, MD, USA
S. D. Kottaridis	Department of Virology, Hellenic Anticancer Institute, Athens, Greece
G. R. F. Krueger	Center of Anatomy II, University of Cologne Medical School, Cologne, Germany
Pat M. Kumar	Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK
Shant Kumar	Department Pathology, University of Manchester Medical School, Manchester, UK
O. D. Laerum	Department of Pathology, The Gade Institute, University of Bergen, Norway
F. J. Lejeune	Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland
S. Linder	Department of Medicine and Health, Linköping University, Linköping, Sweden
L. F. Liu	Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USA
D. M. Lopez	Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA
E. Lundgren	Unit of Applied Cell and Molecular Biology, University of Umeå, Sweden
Y. Maehara	Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
J. Maher	Department of Research Oncology, Division of Cancer Studies, King's College London School of Medicine, Guy's Hospital Campus, London, UK
J. Marescaux	IRCAD, University of Strasbourg, France
J. Mark	Department of Pathology, Kärnshuset, Skövde, Sweden
S. S. Martin	Department of Physiology, University of Maryland School of Medicine, Baltimore, MD, USA
S. Mitra	The Methodist Hospital Research Institute (TMHRI), Houston, TX, USA
S. Miyamoto	Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
S. Moncada	Manchester Cancer Research Centre, University of Manchester, Manchester, UK
M. Mueller	Hochschule Furtwangen University, Villingen-Schwenningen, Germany
F. M. Muggia	New York University Cancer Institute, School of Medicine, NY, USA

- M. Namiki** Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa City, Ishikawa, Japan
- R. Narayanan** Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA
- K. Nilsson** Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden
- S. Pathak** Department of Cell Biology, University of Texas, Houston, TX, USA
- J. L. Persson** Section for Experimental Cancer Research, Clinical Research Center, Lund University, Malmö, Sweden
- G. J. Pilkington** Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK
- C. D. Platsoucas** College of Sciences, Old Dominion University, Norfolk, VA, USA
- A. Polliack** Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel
- D. Rades** Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
- M. Rigaud** Laboratory Biochimie et Génétique Molécules, Faculté de Médecine de Limoges, France
- U. Ringborg** Department of General Oncology, Karolinska Hospital, Stockholm, Sweden
- M. Roselli** Department of Medical Oncology, University of Rome "Tor Vergata", Italy
- S.T. Rosen** Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA
- A. Schauer** Zentrum Pathologie, Georg-August Universität, Göttingen, Germany
- M. Schneider** Department of Organic Chemistry, Bergische University, Wuppertal, Germany
- J. Sehouli** Department of Gynecology, Center for Oncological Surgery, Charité Comprehensive Cancer Center, Berlin, Germany
- A. Seth** Laboratory of Molecular Pathology, Sunnybrook Research Institute and University of Toronto, Ontario, Canada
- G. V. Sherbet** Cancer Research Unit, University of Newcastle-upon-Tyne, UK
- A. Slominski** Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA
- G.-I. Soma** Department of Integrated and Holistic Immunology, Faculty of Medicine, Kagawa University, Kagawa, Japan
- G. S. Stein** Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT, USA
- T. Stigbrand** Department of Immunology, Umeå University, Umeå, Sweden
- T. M. Theophanides** Department of Chemistry, Technical University of Athens, Greece
- P. M. Ueland** Clinical Pharmacology Unit, Department of Pharmacology, University of Bergen, Norway
- H. Van Vlierberghe** Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
- R.G. Vile** Department of Immunology, Mayo Clinic, Rochester, MN, USA
- M. Weller** Department of Neurology, University Hospital Zurich, Zurich, Switzerland
- J. Westermarck** Centre for Biotechnology, University of Turku, Turku, Finland
- B. Westermarck** Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden
- Y. Yen** Taipei Medical University, Taipei, Taiwan, ROC
- M. R. I. Young** Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC, USA
- B. Zumoff** Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA

Acknowledgements

The IAR appreciates the support of the following Foundations, Institutions, Organizations and Universities for the works published in Anticancer Research, Volume 38, 2018.

- Aarne and Aili Turunen Foundation, Finland
 AbbVie Pharmaceuticals, Lake Bluff, IL, U.S.A.
 Academy of Finland, Helsinki, Finland
 Advanced Research Foundation, Department of Neurosurgery, WMCH/New York Medical College, Valhalla, NY, U.S.A.
 Agenzia Regionale per la Tecnologia e l'Innovazione (ARTI), Bari, Italy
 Ajmera Family Chair in Urologic Oncology, University of Toronto, Toronto, ON, Canada
 Albert Einstein Cancer Center, New York, NY, U.S.A.
 Alma Toorock Memorial for Cancer Research, Brooklyn, NY, U.S.A.
 American Chemical Society (ACS) Petroleum Research Fund, Washington, DC, U.S.A.
 American Thoracic Society (ATS), New York, NY, U.S.A.
 Analysis Center of Life Science, Hiroshima University, Hiroshima, Japan
 Anam Hospital, Seoul, Republic of Korea
 Anapole Technologies, Inc., Burlington, IA, U.S.A.
 Anthony and Julianne Capetola Fellowship, Woodbury, NY, U.S.A.
 ARCS Foundation, Torrance, CA, U.S.A.
 Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea
 Asia University, Taichung, Taiwan, R.O.C.
 Associazione "Nastro Viola", Italy
 Associazione "Voglio il Massimo", Naples, Italy
 Associazione Amici Istituto del Radio Olindo Alberti, Brescia, Italy
 Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy
 Associazione Italiana Ricerca Esofago (AIRES), Milan, Italy
 AstraZeneca K.K., Osaka, Japan
 AstraZeneca, Athens, Greece
 Australian Proteome Analysis Facility, National Collaborative Research Infrastructure Scheme (NCRIS), Canberra, Australia
 Austrian Science Fund (FWF), Vienna, Austria
 Avon Cosmetics Company, Gödöllő, Hungary
 Basic Science Research Program, National Research Foundation of Korea (NRF), Ministry of Science, ICT and Future Planning, Gwacheon, Republic of Korea
 Baylor Scott & White Healthcare, Temple, TX, U.S.A.
 Beatrice Hunter Cancer Research Institute, Halifax, NS, U.S.A.
 Ben F. Bryer Foundation Medical Research Fund, Flint, MI, U.S.A.
 Bengt Ihre Foundation, Swedish Society of Medicine, Stockholm, Sweden
 BIH-Charité Clinical Scientist Program, Charité – Universitätsmedizin Berlin and Berlin Institute of Health, Berlin, Germany
 BIO & Medical Technology Development Program, National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea
 Biomedical Center Martin, Jessenius Faculty of Medicine, Martin Comenius University, Bratislava, Slovak Republic
 Biomedical Facility, University College Dublin, Dublin, Ireland
 Bio-oriented Technology Research Advancement Institution (BRAIN), National Agriculture and Food Research Organization (NARO), Japan
 Biostatistics Shared Resource, University of Wisconsin Carbone Cancer, Madison, WI, U.S.A.
 Biostatistics Task Force, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
 Bio-Tech Pharmacal, Inc., Fayetteville, AR, U.S.A.
 Breast Cancer Hope Foundation, London, U.K.
 Bristol-Myers Squibb Co., Ltd, New York, NY, U.S.A.
 British Journal of Anaesthesia (BJA) International Grant 2017, U.K.
 Canadian Breast Cancer Foundation (CBCF), Toronto, ON, Canada
 Canadian Institutes of Health Research, Ottawa, ON, Canada
 Cancer Center Support Grant (CCSG), National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services, Bethesda, MD, U.S.A.
 Cancer Institute Hospital, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan
 Cancer Prevention and Research Institute of Texas, Austin, TX, U.S.A.
 Cancer Research Center, University at Albany (SUNY), Rensselaer, NY, U.S.A.
 Cancer Research Foundation in Northern Sweden, Umeå, Sweden

- Cancer Research Funds of Radiumhemmet, Karolinska Institute, Stockholm, Sweden
- Cancer Society, Stockholm, Sweden
- Cancer Treatment and Research Trust (CTRT), Northwood, U.K.
- Cardiovascular R&D Centre (UnIC), Porto, Portugal
- Catholic University of Korea, Seoul, Republic of Korea
- Center for Advanced Molecular Medicine, Fukuoka University, Fukuoka, Japan
- Center of Innovation Program (COI), Japan Science and Technology Agency (JST), Kawaguchi, Japan
- Central Laboratory, Osaka City University Medical School, Osaka, Japan
- Central Norway Regional Health Authority (RHA), Stjørdal, Norway
- Central Research Institute, Fukuoka University, Fukuoka, Japan
- Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C.
- Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain
- Ceske Budejovice Hospital, Ceske Budejovice, Czech Republic
- Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.
- Chang Gung Medical Research Program, Chang Gung University, Kwei Shan, Taiwan, R.O.C.
- Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C.
- Chang Gung University, Taoyuan, Taiwan, R.O.C.
- Changhua Christian Hospital, Changhua, Taiwan, R.O.C.
- Charles University in Prague, Prague, Czech Republic
- Charles University Research Fund (PROGRES), Charles University in Prague, Prague, Czech Republic
- Cheng Hsin General Hospital, Taipei, Taiwan, R.O.C.
- Chiayi Christian Hospital, Chiayi, Taiwan, R.O.C.
- Chiba Cancer Center, Chiba, Japan
- Chiba University, Chiba, Japan
- Chi-Mei Medical Center, Tainan, Taiwan, R.O.C.
- China Medical University Beigang Hospital, Yunlin, Taiwan, R.O.C.
- China Medical University Hospital, Taichung, Taiwan, R.O.C.
- China Medical University, Taichung, Taiwan, R.O.C.
- China Scholarship Council, Beijing, P.R. China
- Chinese Government
- Chomutov Hospital, Chomutov, Czech Republic
- CHU Amiens Picardie, Amiens, France
- Chugai Pharmaceutical Co., Ltd, Tokyo, Japan
- Chulalongkorn University, Bangkok, Thailand
- Chung Shan Medical University, Taichung, Taiwan, R.O.C.
- Clas Groschinskys Minnesfond, Stockholm, Sweden
- Clinical Medicine Research Laboratory of National Yang-Ming University Hospital, I-Lan, Taiwan, R.O.C.
- Clinical Rebiopsy Bank Project for Comprehensive Cancer Therapy Development, Nippon Medical School, Tokyo, Japan
- Clinical Research Support Center Kyushu (CRoS Kyushu), Fukuoka, Japan
- Clinical Trial and Research Center of Excellence, Ministry of Health and Welfare, Taipei, Taiwan, R.O.C.
- Clinical Trial Center, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
- Collaborative Research Program of the Atomic-bomb Disease Institute, Nagasaki University, Nagasaki, Japan
- Collective Research (IGF), Federal Ministry for Economic Affairs and Energy (BMWi), Berlin, Germany
- College of Agricultural and Life Sciences (CALS) Statistical Consulting Group, University of Wisconsin-Madison, Madison, WI, U.S.A.
- College of Anaesthesiologists of Ireland (CAI), Dublin, Ireland
- Competitive State Research Financing of the Expert Responsibility Area, Tampere University Hospital, Tampere, Finland
- Comprehensive Cancer Center, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
- Conceptual Development of Research Organization, Faculty Hospital in Pilsen, Pilsen, Czech Republic
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brasilia, Brazil
- Conway Institute, Dublin, Ireland
- Cooperation in Science and Technology (COST), EU RTD Framework Program, Brussels, Belgium
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brasilia, Brazil
- Core Facilities of the Faculty of Medicine, Center for Tumor Biology and Immunology, Marburg, Germany
- Council for Science, Technology and Innovation (CSTI), Tokyo, Japan
- County Hospital, Liberec, Czech Republic
- Croatian Science Foundation, Ministry of Science and Education, Zagreb, Republic of Croatia
- Cross-ministerial Strategic Innovation Promotion Program (SIP), Japan
- CureMatch, Inc., San Diego, CA, U.S.A.
- Czech Health Research Council, Prague, Czech Republic
- Czech Science Foundation, Prague, Czech Republic
- Czech University of Life Sciences, Prague, Czech Republic

- Dagmar Ferbs Minnesfond, Stockholm, Sweden
 Daiwa Securities Health Foundation, Tokyo, Japan
 Damp Foundation, Damp, Germany
 Department of Anatomic Pathology, Kyushu University, Fukuoka, Japan
 Department of Anatomy and Cell Biology, Marburg, Germany
 Department of Anesthesiology, University of Regensburg, Regensburg, Germany
 Department of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland
 Department of Biochemistry and Molecular Biology, University of Maryland, Baltimore, MD, U.S.A.
 Department of Biochemistry, University of Wisconsin-Madison, Madison, WI, U.S.A.
 Department of Defense (DoD), Arlington County, VA, U.S.A.
 Department of Diagnostic and Interventional Radiology, Aichi Cancer Hospital, Nagoya, Japan
 Department of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
 Department of Diagnostic Pathology, Yokohama City University Medical Center, Yokohama, Japan
 Department of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan
 Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan
 Department of General Thoracic Surgery, Tokai University Hachioji Hospital,
 Department of Hematology and Oncology, Marburg, Germany
 Department of Hematology and Oncology, Vivantes Klinik am Urban, Berlin, Germany
 Department of Histology and Embryology, Medical University of Wroclaw, Wroclaw, Poland
 Department of Medical Imaging and Radiological Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.
 Department of Medical Research, National Taiwan University Hospital (NTUH), Taipei City, Taiwan, R.O.C.
 Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
 Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
 Department of Orthopedic and Trauma surgery, Ortho-Klinik Dortmund, Dortmund, Germany
 Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Giessen and Marburg, Marburg, Germany
 Department of Pathology and Bioscience, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
 Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI, U.S.A.
 Department of Radiation Oncology, Gunma University Graduate School of Medicine, Japan
 Department of Radiation Oncology, National Defense Medical College, Tokorozawa, Japan
 Department of Radiology, Tokai University School of Medicine Included Hachioji Hospital, Hachioji, Japan
 Department of Surgery, Institute of Health Biosciences, University of Tokushima, Tokushima, Japan
 Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan
 Department of Urology, District Hospital Bad-Hersfeld, Bad Hersfeld, Germany
 Department of Urology, Kyushu University, Fukuoka, Japan
 Department of Urology, Radcliffe Hospital, Cambridge, U.K.
 Department of Urology, University of Heidelberg, Heidelberg, Germany
 Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany
 Deutsche José Carreras Leukämie Stiftung, Munich, Germany
 Deutsche Krebshilfe, Bonn, Germany
 Deutsche Stiftung Dermatologie, Berlin, Germany
 Claudia von Schilling Foundation for Breast Cancer Research, Hannover, Germany
 Discovery Foundation, Dallas, TX, U.S.A.
 Diversity Grant 2017, National Institute of Radiological Sciences (NIRS)-Chiba University, Chiba, Japan
 Division of Isotope Application, Institute for Nuclear Energy Research (INER), Lung-Tan, Taiwan, R.O.C.
 Division of Pathology, Karolinska University Hospital, Solna, Sweden
 Division of Research (DOR), University of Houston, Houston, TX, U.S.A.
 Eccles Breast Cancer Research Fund, Dublin, Ireland
 Edanz Group, Fukuoka, Japan
 Editage, Tokyo, Japan
 Edmond Odette Foundation, Toronto, ON, Canada
 Eisai Co., Ltd., Tokyo, Japan
 Eli Lilly and Company, Indianapolis, IN, U.S.A.
 Eli Lilly Japan K.K., Kobe, Japan
 ELPEN Pharmaceutical Co., Inc., Athens, Greece
 enago™, Tokyo, Japan

- Estonian Society of Clinical Oncologists (EKOS), Estonia
 Ethics Committee, Kobe City Medical Center General
 Hospital, Kobe, Japan
 Ethics Committee, University of Pecs, Pecs, Hungary
 ETHICS project, National Institute for Nuclear Physics
 (INFN), Italy
 Euroanaesthesia 2017, European Society Anaesthesiology
 Project Grant, Brussels, Belgium
 European Regional Development Fund (ERDF), Brussels,
 Belgium
 European School of Oncology (ESO), Milan, Italy
 European Social Fund, Brussels, Belgium
 European Union
 EVO Funds, Helsinki University Hospital, Helsinki,
 Finland
 EVO Funds, Kuopio University Hospital, Kuopio, Finland
 Excellent Research Laboratory, Cancer Molecular Biology
 and Research Center for Cancer Control, Thailand
 Expanded Access Program, Bristol Meyer Squibb, Prague,
 Czech Republic
 Faculty Hospital in Pilsen (FNPI), Pilsen, Czech Republic
 Faculty of Medicine, Songkhla, Thailand
 Faculty of Medicine, University of Szeged, Szeged,
 Hungary
 Faculty Research Grant, Yonsei University College of
 Medicine, Seoul, Republic of Korea
 Far Eastern Memorial Hospital, New Taipei City, Taiwan,
 R.O.C.
 Federal Department of Research and Technology, Germany
 Federal Ministry of Education and Research (BMBF),
 Bonn, Germany
 Finnish Cancer Foundation, Helsinki, Finland
 Finnish Cultural Foundation, Helsinki, Finland
 Finnish Foundation for Cardiovascular Research, Helsinki,
 Finland
 Finnish Government Research Funds, Helsinki, Finland
 Finnish Medical Foundation, Helsinki, Finland
 Finnish Society of Oncology, Helsinki, Finland
 Finnish Work Environment Fund, Helsinki, Finland
 Finnish-Norwegian Medical Foundation, Helsinki, Finland
 Florida A&M University, Tallahassee, FL, U.S.A.
 Fondazione Arpa, Pisa, Italy
 Fondazione Luigi e Gabriella D'Amato Onlus, Rome, Italy
 Fondo Nacional de Desarrollo Científico y Tecnológico
 (FONDECYT), Santiago, Chile
 Forschungskommission, Faculty of Medicine, University of
 Freiburg, Freiburg, Germany
 FORSS-Medical Research Council of Southeast Sweden,
 Linköping, Sweden
 Foundation of Clinical Cancer Research, Jönköping, Sweden
 French National Alliance for Life Sciences and Health
 (AVIESAN), France
 French Programme Hospitalier de Recherche Clinique,
 Ministry of Health, France
 Friedrich-Baur-Foundation, Altenkunstadt, Germany
 Fundação Amazônia Paraense do Estado do Pará
 (FAPESPA), São Paulo, Brazil
 Fundação de Amparo a Pesquisa do Estado de Minas
 Gerais (FAPEMIG), Ipatinga, Brazil
 Fundação de Amparo à Pesquisa do Estado de São Paulo
 (FAPESP) São Paulo, Brazil
 Fundação de Apoio ao Desenvolvimento do Ensino,
 Ciência e Tecnologia (FUNDECT) do Estado de Mato
 Grosso do Sul, Campo Grande, Brazil
 Fundação para a Ciência e a Tecnologia (FCT), Ministério
 da Ciência e Ensino Superior, Portugal
 Fundación Mututa Madrileña, Madrid, Spain
 Funding Project of Jiangsu Province, Jiangsu, P.R. China
 Fundo Europeu de Desenvolvimento Regional (FEDER),
 Lisbon, Portugal
 Futuro in Ricerca (FIRB)/ Medical Research in Italy
 (MERIT) Project, Ministry of Economic Development
 (MISE), Italy
 Futurum Academy for Health and Care, Region Jönköping
 County, Sweden
 Gene Research Center, Yamaguchi University, Yamaguchi,
 Japan
 Genentech, Inc., South San Francisco, CA, U.S.A.
 General University Hospital, Prague, Czech Republic
 Genesis Research Trust, Garfield Weston Foundation,
 London, U.K.
 German Cancer Aid (Deutsche Krebshilfe e.V.), Bonn,
 Germany
 German Federal Ministry of Education and Research
 (BMBF), Bonn, Germany
 German Federation of Industrial Research Associations
 (AiF), Köln, Germany
 GeSeTON Project, Ministry of Economic Development
 (MISE), Italy
 Great Plains IDEa-CTR Pilot Grant, University of
 Nebraska Medical Center, Omaha, NE, U.S.A.
 Grigore T. Popa University of Medicine and Pharmacy,
 Iasi, Romania
 Grimes Family Foundation Endowment in Gynecologic
 Oncology, Texas A&M Health Science Center, Temple,
 TX, U.S.A.
 Guangdong Science and Technology Department,
 Guangzhou, P.R. China

- Gundersen Medical Foundation, La Crosse, WI, U.S.A.
 Gunma Breast Clinical Conference Study Group (GBCCSG),
 Gunma University Clinical Biobank, Maebashi, Japan
 Gunma University Graduate School of Medicine, Gunma, Japan
 Gunma University, Gunma, Japan
 Hallym University Research Fund, Chuncheon, Republic of Korea
 Has Tavuk, Nilufer-Bursa, Turkey
 HD Pharma, Ladenburg, Germany
 Heikki, Aino and Aarne Korhonen Foundation, Finland
 Heinz and Heide Duerr Foundation, Berlin, Germany
 Hidaka Hospital, Takasaki, Japan
 Histology Laboratory, Moffitt Cancer Center, Tampa, FL, U.S.A.
 Histology Section, Tissue Core, Moffitt Cancer Center and Research Institute, Tampa, FL, U.S.A.
 Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, U.S.A.
 Horizon 2020 Programme, European Commission, Brussels, Belgium
 Horizont Kinderkrebshilfe Weseke e.V., Borken, Germany
 Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil
 Hualien Tzu-Chi Hospital, Hualien, Taiwan, R.O.C.
 Hyogo College of Medicine, Nishinomiya, Japan
 Ida Montin Foundation, Finland
 Iga City General Hospital, Iga, Japan
 Inoue Enryou Memorial Foundation, Toyo University, Tokyo, Japan
 Institut de Génétique et Biologie Moléculaire et Cellulaire (IGBMC), Illkirch-Graffenstaden, France
 Institut de la Santé et la Recherche Médicale (INSERM), Paris, France
 Institute of Biomathematics, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
 Institute of Cancer Research, London, U.K.
 Institute of Pathology, University of Ljubljana, Ljubljana, Slovenia
 Institute of Polish Mother's Memorial Hospital, Lodz, Poland
 Institute of Translational Health Sciences (ITHS), Seattle, WA, U.S.A.
 Institutional Biobank (BBI), G. Pascale Foundation, National Tumor Institute, Naples, Italy
 Instituto de Biomedicina da Universidade de Aveiro (iBiMED), Aveiro, Portugal
 Instituto de Salud Carlos III (ISCIII), Madrid, Spain
 Instituts Thématiques Multi-Organismes (ITMO), France
 Interdisciplinary Center for Exposures, Diseases, Genomics and Environment, University of Washington, Seattle, WA, U.S.A.
 International Cancer Center, Osaka, Japan
 Interreg Deutschland-Danmark, Kiel, Germany
 Inui Immunotherapy Clinic, Osaka, Japan
 Iowa Science Foundation Grant, Cedar Falls, IA, U.S.A.
 Ipsen SpA., Paris, France
 Ishii Medical Clinic, Mito, Japan
 Italian Association for Cancer Research (AIRC), Milan, Italy
 Italian Ministry of Education, University and Research (MIUR), Rome, Italy
 Italian Ministry of Health Animal Care and Use Committee, Italy
 Izumo City Supporting Cancer Research Project (ICSCR), Izumo, Japan
 Jagiellonian University Medical College, Kraków, Poland
 Jan Kochanowski University, Kielce, Poland
 Jane and Aatos Erkkö Foundation, Helsinki, Finland
 János Bolyai Research Scholarship, Hungarian Academy of Sciences (MTA), Budapest, Hungary
 Japan Agency for Medical Research and Development (AMED), Tokyo, Japan
 Japan Society for the Promotion of Science, (JSPS), Tokyo, Japan
 Japanese Breast Cancer Society, Fukuoka, Japan
 Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan
 JCHO Osaka Hospital, Osaka, Japan
 Jeju Science High School, Jeju, Republic of Korea
 Jensen-Jarolim Laboratory, Medical University of Vienna, Vienna, Austria
 Jihlava Hospital, Jihlava, Czech Republic
 JMC, Ltd., Yokohama, Japan
 JSS Young Researcher Award, Japan Surgical Society, Tokyo, Japan
 Kaibara Morikazu Medical Science Promotion Foundation, Japan
 Kakihara Science and Technology Foundation, Fukuoka, Japan
 KAKENHI, Tokyo, Japan
 Kanagawa Cancer Center, Kanagawa, Japan
 Kanagawa Prefectural Hospitals Cancer Fund, Kanagawa, Japan
 Kanazawa University, Kanazawa, Japan
 Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, R.O.C.

- Karl-Olga Hospital, Stuttgart, Germany
 Karolinska Institutet, Solna, Sweden
 Katharinen Hospital, Stuttgart, Germany
 Keio University, Tokyo, Japan
 Key Laboratory of Malignant Tumour Gene Regulation and Target Therapy, Guangdong Higher Education Institutes, Guangzhou, P.R. China
 Key Laboratory of Malignant Tumour Molecular Mechanism and Translational Medicine, Guangzhou Bureau of Science and Information Technology, Guangzhou, P.R. China
 Key Science Fund, Hangzhou Health Bureau, Hangzhou, P.R. China
 King Gustav V Jubilee Fund, Stockholm, Sweden
 King's College, London, U.K.
 Kinki University, Higashi-Osaka, Japan
 Kitasato University Medical Center, Kitamoto, Japan
 Kitasato University Research Grant for Young Researchers, Tokyo, Japan
 Klinikum Stuttgart, Stuttgart, Germany
 Knut & Alice Wallenberg Foundation, Uppsala, Sweden
 Kobe City Medical Center General Hospital, Kobe, Japan
 Korea Drug Development Fund (KDDF), Seoul, Republic of Korea
 Korea Health Technology R&D Project, Korea Health Industry Development Institute (KHIDI), Ministry of Health & Welfare, Seoul, Republic of Korea
 Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (iPET), Anyang, Republic of Korea
 Korea Institute of Radiological and Medical Sciences (KIRAMS), Ministry of Science, ICT and Future Planning (MSIP), Gwacheon, Republic of Korea
 Korea National University of Transportation, Chungju, Republic of Korea
 Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea
 Korea University Grant, Seoul, Republic of Korea
 Korea University Medical Center, Seoul, Republic of Korea
 Korean Society of Gastrointestinal Cancer, Seoul, Republic of Korea
 Korean Society of Pathologists Grant, Seoul, Republic of Korea
 Kotake Laboratory, Kindai University, Iizuka, Japan
 Kristianstad University, Kristianstad, Sweden
 Kumamoto University Hospital, Kumamoto, Japan
 Kumamoto University, Kumamoto, Japan
 Kuopio University Hospital, Kuopio, Finland
 Kyoto Prefectural University of Medicine, Kyoto, Japan
 Kyung Hee University, Seoul, Republic of Korea
 Kyushu University, Fukuoka, Japan
 Laboratorio Universitario di Ricerca Medica (LURM) Research Center, University of Verona, Verona, Italy
 Laboratory Medicine Ryhov County Hospital, Jönköping, Sweden
 Latvian Council of Science, Riga, Latvia
 Latvian National Research Programme BIOMEDICINE 2014-2017, Riga, Latvia
 LCMicro-UCS and Cytogene Molecular Diagnostics Company, Lajeado, Brazil
 Leadiant Biosciences, Gaithersburg, MD, U.S.A.
 Leading Graduate Schools and Cultivating Global Leaders, Heavy Ion Therapeutics and Engineering, Gunma University, Maebashi, Japan
 Leading Graduate Schools, Cultivating Global Leaders in Heavy Ion Therapeutics and Engineering, Gunma University, Maebashi, Japan
 Leading National Research Center (KNOW), Wrocław Center for Biotechnology, Wrocław, Poland
 Life Mate Co., Ltd., Bletchley, U.K.
 Ligue Contre le Cancer, Comité de la Somme, Amiens, France
 Liver Research Center, Chang Gung Memorial Hospital, Taoyuan City, Taiwan, R.O.C.
 Liwen Bianji, Edanz Group China, Beijing, P.R. China
 Maccabi Health Services, Health Maintenance Organizations (HMO), Tel Aviv, Israel
 Magnetic Health Science Foundation, Japan
 Magnus Bergvalls Stiftelse, Stockholm, Sweden
 Marienhospital, Stuttgart, Germany
 Marine Biotechnology Program, Ministry of Oceans and Fisheries, Sejong, Republic of Korea
 Mário Dias Teixeira Veterinary Hospital, Federal Rural University of Amazonia, Belem, Brazil
 Márton Áron Research Programme, Ministry of Foreign Affairs and Trade, Budapest, Hungary
 Mary och Georg C. Ehrnrooths Stiftelse, Nordea, Finland
 Masaryk Hospital, Usti nad Labem, Czech Republic
 Masaryk Memorial Institute of Oncology, Brno, Czech Republic
 Medical Center of the University of Munich - LMU Munich, Munich, Germany
 Medical Funds for Special Diseases in Key Department of Hangzhou, Hangzhou, P.R. China
 Medical Oncology Unit, Tor Vergata Clinical Center, Rome, Italy
 Medical Research Center Oulu, University of Oulu Scholarship Foundation, Oulu, Finland

- Medical Research Center Program, Republic of Korea
 Medical Research Core Facilities Center, Office of
 Research & Development, China Medical University,
 Taichung, Taiwan, R.O.C.
 Medical School, University of Athens, Athens, Greece
 Medical University in Wroclaw, Wroclaw, Poland
 Medicine, Odontology and Health (ALF), Stockholm, Sweden
 Mediterranean Cancer Support and Rehabilitation –
 Medicare Onlus, Catania, Italy
 Mellrákinfo, Budapest, Hungary
 Melvin Markey Discovery Fund, Cleveland Clinic,
 Cleveland, OH, U.S.A.
 Min-Hwei College of Health Care Management, Tainan,
 Taiwan, R.O.C.
 Ministry of Agriculture, Forestry and Fisheries, Tokyo,
 Japan
 Ministry of Aliyah and Immigrant Absorption, Tel Aviv,
 Israel
 Ministry of Economic Development, Rome, Italy
 Ministry of Education, Culture, Sports, Science and
 Technology (MEXT), Tokyo, Japan
 Ministry of Education, Science, Research, and Sport,
 Bratislava, Slovak Republic
 Ministry of Education, Youth and Sports, Prague, Czech
 Republic
 Ministry of Foreign Affairs and Trade, Rabat, Morocco
 Ministry of Health, Labor and Welfare, Tokyo, Japan
 Ministry of Health of the Czech Republic, Prague,
 Czech Republic
 Ministry of Health, Rome, Italy
 Ministry of Science and Higher Education of Poland,
 Warsaw, Poland
 Ministry of Science and ICT (MSIT), Gwacheon,
 Republic of Korea
 Ministry of Science and Technology (MOST), Taipei,
 Taiwan, R.O.C.
 Ministry of Science and Technology, Beijing, P.R. China
 Ministry of Science, ICT and Future Planning (MSIP),
 Republic of Korea
 Minneapolis VA Medical Center, Minneapolis, MN, U.S.A.
 Motol University Hospital, Prague, Czech Republic
 MSU Internal Funding, Michigan State University, East
 Lansing, MI, U.S.A.
 Myongji Hospital, Goyang, Republic of Korea
 Na Homolce Hospital, Prague, Czech Republic
 Naito Foundation, Tokyo, Japan
 Nanjing Medical University, Nanjing, P.R. China
 National Cancer Center Research and Development Fund,
 Tokyo, Japan
 National Cancer Institute (NCI), National Institutes of
 Health, Department of Health and Human Services,
 Bethesda, MD, U.S.A.
 National Centre for Research and Development in Poland,
 Warsaw, Poland
 National Committee for Scientific Research, Warsaw,
 Poland
 National Health Research Institutes, Taipei, Taiwan R.O.C.
 National Health Service Funding, National Institute for
 Health Research (NIHR) Biomedical Research Centre
 (BRC), U.K.
 National Hospital Organization, Kyushu Cancer Center,
 Fukuoka, Japan
 National Institute for General Medical Science (NIGMS),
 National Institutes of Health (NIH), Department of
 Health and Human Services, Bethesda, MD, U.S.A.
 National Institute for Health Research (NIHR) Royal
 Marsden (RM) Institute of Cancer Research (ICR)
 Biomedical Research Centre, London, U.K.
 National Institute of Allergy and Infectious Diseases
 (NIAID), National Institutes of Health (NIH),
 Department of Health and Human Services, Bethesda,
 MD, U.S.A.
 National Institute of Environmental Health Sciences
 (NIEHS), National Institutes of Health (NIH),
 Department of Health and Human Services, Bethesda,
 MD, U.S.A.
 National Institutes of Health (NIH), Department of Health
 and Human Services, Bethesda, MD, U.S.A.
 National Natural Science Foundation of China, Guangdong,
 P.R. China
 National R&D Program for Cancer Control, Ministry of
 Health & Welfare, Sejong, Republic of Korea
 National Research Foundation of Korea (NRF), Ministry of
 Education, Science and Technology, Seoul, Republic of
 Korea
 National Research Foundation of Korea (NRF), Ministry of
 Science, ICT and Future Planning (MSIP), Republic of
 Korea
 National Science Center (NCN), Krakow, Poland
 National Science Council, Executive Yuan, Taipei, Taiwan,
 R.O.C.
 National Sustainability Program I (NPU I), Ministry of
 Education Youth and Sports, Prague, Czech Republic
 National Taiwan University Hospital, Taipei, Taiwan,
 R.O.C.
 National Yang-Ming University Hospital, I-Lan, Taiwan,
 R.O.C.
 Natural Science Foundation of China, P.R. China

- Natural Science Foundation of Zhejiang Province, Zhejiang, P.R. China
- New Brunswick Health Research Foundation (NBHRF), Fredericton, NB, Canada
- New Brunswick Innovation Foundation (NBIF), Fredericton, NB, Canada
- NIH Tetramer Core Facility at Emory University, Emory University Vaccine Center, Atlanta, GA, U.S.A.
- Nihon CLEAN Co., Ltd., Osaka, Japan
- Nikon Instruments, Minneapolis, MN, U.S.A.
- Noble Centennial Endowment for Research in Obstetrics and Gynecology, U.S.A.
- Norwegian Cancer Society, Oslo, Norway
- Norwegian University of Science and Technology (NTNU), Trondheim, Norway
- Novartis Farma SpA, Origgio, Italy
- Novartis International AG, Basel, Switzerland
- Novartis Pharma GmbH, Nuremberg, Germany
- Novy Jicin Hospital, Novy Jicin, Czech Republic
- Nucis e.V. Deutschland, Hamburg, Germany
- Office of Research Royalty Research Fund, University of Washington, Seattle, WA, U.S.A.
- OITA Cancer Research Foundation, Yufu, Japan
- Olympia Diagnostics, Inc., Sunnyvale, CA, U.S.A.
- Operational Programme Competitiveness and Internationalization (COMPETE 2020), Lisbon, Portugal
- Operational Programme Research and Innovation, European Regional Development Fund (ERDF), Brussels, Belgium
- ORGANOGENIX, Inc., Kanagawa, Japan
- Osaka Police Hospital, Osaka, Japan
- Osaka University, Osaka, Japan
- Oslo University Hospital – Radiumhospitalet, Oslo, Norway
- Otto A. Malm Foundation, Helsinki, Finland
- Ovarian Cancer Action, London, U.K.
- Oxford PharmaGenesis, Inc., Newtown, PA, U.S.A.
- Paavo and Eila Salonen Legacy, Finland
- Parker Hannifin Foundation, Cleveland, OH, U.S.A.
- Pedagogical University of Kracow, Krakow, Poland
- Peking University Third Hospital, Beijing, P.R. China
- Peking University, Beijing, P.R. China
- Peter T. Rowley Breast Cancer Research Grant, New York State Department of Health, Albany, NY, U.S.A.
- Pfizer Pharma GmbH, Karlsruhe, Germany
- Pfizer, Inc., New York City, NY, U.S.A.
- Pirkanmaa Cancer Society, Finland
- Pirkanmaa Hospital District, Finland
- Pirkanmaa Regional Fund, Finland
- Polish Development Fund, Warsaw, Poland
- Polistudium, Milan, Italy
- Postgraduate Research & Practice Innovation Program, Jiangsu Province, P.R. China
- Prince of Songkla University (PSU), Hat Yai, Thailand
- Princess Takamatsu Cancer Research Fund, Tokyo, Japan
- Priority Issue on Post-K Computer, Tokyo, Japan
- Probat-Werke von Gimborn Maschinenfabrik GmbH, Emmerich, Germany
- Program for Career Development of Young Scientists and Ph.D. Students, Bulgarian Academy of Sciences, Sofia, Bulgaria
- Program for the Strategic Research Foundation at Private Universities, Ministry of Education, Culture, Sports, Science and Technology of Japan, Tokyo, Japan
- Project for Cancer Research and Therapeutic Evolution (PCREATE), Japan Agency for Medical Research and Development (AMED), Tokyo, Japan
- Project Violet, Fred Hutchinson Cancer Research Center, Seattle, WA, U.S.A.
- QEII Foundation, Halifax, NS, Canada
- Quadro de Referência Estratégica Nacional (QREN), Lisbon, Portugal
- R&D Laboratory for Innovative Biotherapeutics Science, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan
- Radiotherapy Ward, Department of Oncology, Ryhov County Hospital, Jönköping, Sweden
- Ratchadaphisek Somphot Endowment Fund, Chulalongkorn University, Bangkok, Thailand
- Rays of Hope Charity, Leeds Teaching Hospitals Charitable Foundation, Leeds, U.K.
- Rede Nacional de Espectrometria de Massa (RNEM), Portugal
- Regensburger Forschungsfoerderung in der Medizin (ReForM), University of Regensburg, Regensburg, Germany
- Regional Agreement on Medical Training and Clinical Research (ALF), Stockholm County Council and Karolinska Institute, Stockholm, Sweden
- Research and Creative Activities Fund, University of Michigan-Flint, Flint, MI, U.S.A.
- Research and Development for Innovations Operational Program, European Regional Development Fund and Czech Republic
- Research and Development Fund, National Cancer Center and Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED), Tokyo, Japan

- Research and Education (R&E) 2017, Jeju Science High School, Jeju, Republic of Korea
- Research Association of the German Food Industry (FEI), Bonn, Germany
- Research Center for Advanced Molecular Medicine, Fukuoka University, Fukuoka, Japan
- Research Center for Molecular Medicine, Faculty of Medicine of Hiroshima University, Hiroshima, Japan
- Research Council of Lithuania, Vilnius, Lithuania
- Research Fund of Istanbul University, Istanbul, Turkey
- Research Fund, Tung's Taichung MetroHarbor Hospital, Taichung City, Taiwan, R.O.C.
- Research Grant, Yonsei University College of Medicine, Seoul, Republic of Korea
- Research Project of Gunma University Heavy Ion Medical Center, Maebashi, Japan
- Research Project of Jinling Hospital, Nanjing, P.R. China
- Research Project with Heavy Ions at the National Institute of Radiological Sciences, Chiba, Japan
- Research Promotion Grant, Shin-Nihon Advanced Medical Research Foundation, Japan
- Research Promotion Grant, Takeda Science Foundation, Osaka, Japan
- Research Service of the Minneapolis Veterans Affairs Medical Center, Minneapolis, MN, U.S.A.
- Research Services Council Collaborative Grant, University of Nebraska at Kearny (UNK), Kearney, NE, U.S.A.
- Research Western Internal Research Programs, University of Western Ontario, London, ON, Canada
- Robert Bosch Stiftung, Stuttgart, Germany
- Roche Farma S.A., Spain
- Roche S.A.S., Paris, France
- Royal College of Surgeons Fellowship, London, U.K.
- Royal Marsden NHS Foundation Trust, London, U.K.
- Royal Swedish Academy of Sciences, Stockholm, Sweden
- Ruth and Rickard Juhlin Foundation, Stockholm, Sweden
- Sabine-Döriges-Stiftung für krebskranke Kinder und Jugendliche, Möglingen, Germany
- Safety Monitoring Committee, Japan
- Sahlgrenska Academy, University of Gothenburg, Region Västra Götaland, Sweden
- Sahlgrenska Hospital Funds, Gothenburg, Sweden
- Saint Mary's Hospital Luodong, Yilan, Taiwan, R.O.C.
- Samsung Medical Center BioBank, Seoul, Republic of Korea
- San Giovanni Hospital-Addolorata, Rome, Italy
- Sanming Project of Medicine, Shenzhen, P.R. China
- Sanofi S.A., Paris, France
- Sapporo Medical University, Sapporo, Japan
- School of Medicine, Fukushima Medical University, Fukushima, Japan
- School of Pharmaceutical Sciences and Pharmacy, Hokkaido University, Sapporo, Japan
- School of Pharmacy, Nihon University, Tokyo, Japan
- Science and Technology Foundation of Shenzhen, Shenzhen, P.R. China
- Science and Technology Programme of Guangzhou, Guangzhou, P.R. China
- Sciencons AS, Oslo, Norway
- Scientific and Technological Research Council of Turkey (TUBITAK), Ankara, Turkey
- Scientific Research Project Coordination Unit, Istanbul University, Istanbul, Turkey
- Seppo Nieminen Fund, Finland
- Seventh Framework Programme - CORDIS, European Commission, Brussels, Belgium
- Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan, R.O.C.
- Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.
- Sigrid Jusélius Foundation, Helsinki, Finland
- Sigurd and Elsa Goljes Foundation, Sweden
- Simon Fraser University, Burnaby, BC, Canada
- Slovak Grant Agency, Bratislava, Slovakia
- SNP & SEQ Technology Unit, Uppsala, Sweden
- SNUBH Research Fund, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
- Spartan Innovations, Michigan State University (MSU), East Lansing, MI, U.S.A.
- St. Anna University Hospital, Brno, Czech Republic
- St. Luke's Medical Center, Manila, Philippines
- St. Savvas Regional Anticancer Oncology Hospital of Athens, Athens, Greece
- State of Hungary
- Stiftelsen Sigurd & Elsa Goljes Minne, Stockholm, Sweden
- Stiftung Integrative Medizin, Stuttgart, Germany
- Stiftung Tumorforschung Kopf-Hals, Wiesbaden, Germany
- Stockholm Cancer Society, Stockholm, Sweden
- Stockholm City Council, Stockholm, Sweden
- Stockholm County ALF, Stockholm, Sweden
- Strategische Forschungsverbund, Heinrich Heine University, Dusseldorf, Germany
- Svenska Läkarsällskapet (SLS), Stockholm, Sweden
- Svenska Sällskapet för Medicinsk Forskning (SSMF), Stockholm, Sweden
- Swedish Breast Cancer Association, Stockholm, Sweden
- Swedish Cancer and Allergy Foundation, Stockholm, Sweden

- Swedish Cancer Foundation, Stockholm, Sweden
 Swedish Cancer Society, Stockholm, Sweden
 Swedish Foundation for Higher Education and Cooperation, Stockholm, Sweden
 Swedish International Development Cooperation Agency (SIDA), Stockholm, Sweden
 Swedish Society for Medical Research (SSMF), Stockholm, Sweden
 Sydney Vital Translational Cancer Research Centre, St. Leonards, Australia
 Szeged Foundation for Cancer Research, Szeged, Hungary
 T Bata Memorial Hospital, Zlin, Czech Republic
 Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
 Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan, R.O.C.
 Taiho Pharmaceutical Co., Ltd., Tokyo, Japan
 Taipei Medical University Hospital, Taipei, Taiwan, R.O.C.
 Taipei Medical University, Taipei, Taiwan, R.O.C.
 Taiwan Ministry of Health and Welfare (MOHW), Taipei, Taiwan, R.O.C.
 Taiwan Ministry of Science and Technology (MOST), Taipei, Taiwan, R.O.C.
 Takeda Science Foundation, Japan
 Társadalmi Megújulás Operatív Program (TÁMOP), Hungary
 Tartu University Hospital, Tartu, Estonia
 Terry Fox Cancer Research Lab, Taipei, Taiwan, R.O.C.
 Terry Fox Strategic Health Research Training Program in Cancer Research, Canadian Institutes of Health Research (CIHR), Ottawa, ON, Canada
 Texas A&M Irma Lerma Rangel College of Pharmacy, Kingsville, TX, U.S.A.
 Thailand Research Fund, Bangkok, Thailand
 The Discovery Foundation, Dallas, TX, U.S.A.
 The Leading National Research Centre (KNOW), Wrocław Centre of Biotechnology, Wrocław, Poland
 Thomayer Hospital, Prague, Czech Republic
 Tissue Bank, China Medical University, Taichung, Taiwan R.O.C.
 Tissue Biology & Electron Microscopy Research Center, Kawasaki Medical School, Kurashiki, Japan
 Tissue Culture Research Center, Kawasaki Medical School, Kurashiki, Japan
 Toho University, Tokyo, Japan
 Tokushima Laboratory of Taiho Pharmaceutical, Tokushima, Japan
 Tokushima University Graduate School, Tokushima, Japan
 Tokyo Cooperative Oncology Group, Tokyo, Japan
 Tokyo Medical and Dental University, Tokyo, Japan
 Tokyo Teishin Hospital, Tokyo, Japan
 Tokyo University of Science, Tokyo, Japan
 Tor Vergata Breast Cancer Unit, Rome, Italy
 Toranomon Hospital, Tokyo, Japan
 Tore Nilsons Fond, Stockholm, Sweden
 Toyo University, Tokyo, Japan
 Translational Laboratory, Department of Medical Research, Taipei Medical University Hospital, Taipei, Taiwan, R.O.C.
 Translational R&D Project, Institute for Bio-Medical Convergence, Incheon St. Mary's Hospital, Incheon, Republic of Korea
 TRI, Kobe, Japan
 TTY Biopharm, Taipei, Taiwan, R.O.C.
 TUA Research Funding, Sweden
 Tumour and Angiogenesis Research Group, Athens, Greece
 Turku University Hospital, Turku, Finland
 UCLA Intellectual and Developmental Disability Research Center (IDDR), Los Angeles, CA, U.S.A.
 Undergraduate Research Opportunity Program, University of Michigan-Flint, Flint, MI, U.S.A.
 Unidade de Investigação de Química Orgânica, Produtos Naturais e Agroalimentares (QOPNA), University of Aveiro, Aveiro, Portugal
 University Hospital Medical Information Network (UMIN) Clinical Trial Registry, UMIN Center, University of Tokyo Hospital, Tokyo, Japan
 University Hospital of Oulu, Oulu, Finland
 University Hospital Plzen, Pilsen, Czech Republic
 University Hospital, Brno, Czech Republic
 University Hospital, Hradec Kralove, Czech Republic
 University Hospital, Ostrava, Czech Republic
 University of Iowa, Iowa City, IA, U.S.A.
 University of Minnesota, Minneapolis, MN, U.S.A.
 University of Pecs, Pecs, Hungary
 University of Szeged, Szeged, Hungary
 University of Tokyo Hospital, Tokyo, Japan
 University of Verona, Verona, Italy
 University of Warmia and Mazury in Olsztyn, Olsztyn, Poland
 University of Western Ontario, London, ON, Canada
 UNKP-17-3 New National Excellence Program, Ministry of Human Capacities, Hungary
 Uppsala Universitet International Science Programme (ISP), Uppsala, Sweden
 Uppsala University, Uppsala, Sweden

Urologic Surgery, VA Medical Center, Minneapolis, MN, U.S.A.

Vanderbilt Digestive Disease Research Center, Nashville, TN, U.S.A.

Ventana Medical Systems Inc., Oro Valley, AZ, U.S.A.

Victor Babes University of Medicine and Pharmacy, Timisoara, Romania

Vitamin D Council, San Luis Obispo, CA, U.S.A.

Vitamin D Society, Woodstock, ON, Canada

VMC Flow Cytometry Shared Resource, Vanderbilt Ingram Cancer Center, Nashville, TN, U.S.A.

Wallace Academic Editing, Taipei, Taiwan, R.O.C.

WanFang Hospital, Taipei, Taiwan, R.O.C.

Warsaw University of Technology, Warsaw, Poland

Welcome Trust and Cancer Research UK, U.K.

Wilkes University, Wilkes-Barre, PA, U.S.A.

William and Ella Owen Medical Research Foundation, San Antonio, TX, U.S.A.

Wirtschafts-und Infrastrukturbank Hessen, Frankfurt am Main, Germany

Working Group for Esophageal Cancer, National Institute of Radiological Sciences, Chiba, Japan

Working Group of Gynecological Tumors, Japan

Wroclaw Medical University, Wroclaw, Poland

Yamagata University, Yamagata, Japan

YCU Center for Novel and Exploratory Clinical Trials (Y-NEXT), Yokohama, Japan

Yeungnam University Research Grant, Gyeongsan, Republic of Korea

Yokohama Clinical Oncology Group (YCOG), Yokohama, Japan

Zhejiang Provincial Natural Science Foundation, Zhejiang, P.R. China

Zuoying Branch of Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan, R.O.C.

Instructions for Authors 2019

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Conflicts of Interest*; (h) *Authors' contributions*; (i) *Acknowledgements*; (j) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973. References should include PMID and DOI (if applicable).

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html> In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email (iar@iar-anticancer.org) within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions for authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to AR.
 - plagiarism is detected by plagiarism screening services.(Rejection rate (2016): 66%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iia-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2019 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Reviews